Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03945188 · ClinicalTrials.gov registry record · Phase 3
Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
A Phase 3 study, sponsored by Arena Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 433
- Enrollment target
NCT03945188 is a Phase 3 study that has completed, run by Arena Pharmaceuticals. The registered enrollment target is 433 participants.
The verdict
NCT03945188, a Phase 3 study, has completed, sponsored by Arena Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 433 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for moderately to severely active ulcerative colitis.
Interventions
- DRUG Placebo
- DRUG Etrasimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 433 participants |
| Start Date | 2019-06-13 |
| Est. Completion | 2022-02-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03945188
The ClinicalTrials.gov registry entry for NCT03945188 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 433 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arena Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03945188 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03945188 about?
NCT03945188 is a clinical study titled "Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis". The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for moderately to severely active ulcerative colitis.
What is the current status of trial NCT03945188?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 433 participants. The study started on 2019-06-13. Estimated completion is 2022-02-16.
What interventions are being tested in trial NCT03945188?
The interventions under investigation include: Placebo (DRUG), Etrasimod (DRUG).
Who is sponsoring clinical trial NCT03945188?
This trial is sponsored by Arena Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.